Risks

Weak liquidity and sub-1.0 current ratio increase refinancing and working-capital pressure versus better-capitalized peers, limiting flexibility if demand softens.

Very low interest coverage versus peers with stronger earnings buffers raises sensitivity to rate or margin shocks, making debt service a more material downside driver.

Long cash conversion cycle driven by elevated receivables and inventory days versus peers ties up cash, constraining growth funding and amplifying execution risk.

High leverage relative to earnings capacity leaves BIOX more exposed than peers to covenant or capital-market stress, especially if operating performance remains uneven.

Opportunities

Negative net debt to EBITDA suggests a cash-rich balance sheet versus leveraged peers, creating optionality for funding growth or absorbing volatility.

If BIOX sustains working-capital normalization, cash release could improve liquidity faster than peers with structurally tighter cycles, supporting operating flexibility.

Lower net leverage than many industrial peers can preserve strategic capacity in a downturn, improving relative resilience if external demand weakens.

Any improvement in receivables collection or inventory turns would translate into outsized cash flow upside versus peers with already efficient conversion cycles.

Overall Score

BIOX shows some balance-sheet optionality from negative net debt, but weak liquidity, poor interest coverage, and a stretched cash conversion cycle keep forward positioning only modestly above peers.